Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis
Alemtuzumab leads to the normalization of sNfL values in MS patients after 2 years of treatment, with no apparent effect on sGFAP values.
Authors
- Juan Luis Chico García
- Alexander Rodero Romero
- Jaime Masjuán (ORCID: https://orcid.org/0000-0003-1329-0943)
- Enric Monreal (ORCID: https://orcid.org/0000-0003-3293-0125)
- José Ignacio Fernández-Velasco (ORCID: https://orcid.org/0000-0001-9148-671X)
- Raquel Sainz-Amo
- Noelia Villarrubia (ORCID: https://orcid.org/0000-0002-2114-8632)
- Lucienne Costa‐Frossard (ORCID: https://orcid.org/0000-0002-6512-4413)
- Luisa María Villar (ORCID: https://orcid.org/0000-0002-9067-3668)
- Susana Sainz de la Maza (ORCID: https://orcid.org/0000-0001-8605-0049)
- José Luis Veiga González
- Fernando Rodríguez Jorge
Institutions
- Instituto de Salud Carlos III (ES)
- Spanish Multiple Sclerosis Network (ES)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-08-19
- DOI
- https://doi.org/10.3389/fimmu.2024.1454474
- Citations
- 8
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.40
Funders
- Instituto de Salud Carlos III
- European Regional Development Fund